Perceptions and Barriers to Outpatient Antiviral Therapy for COVID-19 and Influenza as Observed by Infectious Disease Specialists in North America: Results of an Emerging Infections Network (EIN) Survey, February 2024
Antiviral therapy is underutilized for outpatients at increased risk for severe COVID-19 or influenza. Results from this survey offer insights into treatment barriers from the infectious disease specialist perspective. Further education is needed about the benefits of early antiviral therapy.
Authors
- Pragna Patel (ORCID: https://orcid.org/0000-0003-1386-8194)
- Souci Louis (ORCID: https://orcid.org/0009-0005-9754-8279)
- Susan E. Beekmann (ORCID: https://orcid.org/0000-0003-0278-506X)
- Jessica N. Ricaldi
- Timothy M. Uyeki (ORCID: https://orcid.org/0000-0001-5338-8668)
- Philip M. Polgreen (ORCID: https://orcid.org/0000-0002-0630-5898)
- Dallas J. Smith (ORCID: https://orcid.org/0000-0001-5707-528X)
- Anastasia S. Lambrou (ORCID: https://orcid.org/0000-0001-6822-9969)
- Shikha Garg (ORCID: https://orcid.org/0000-0002-9345-6669)
- Scott Santibañez (ORCID: https://orcid.org/0000-0003-3505-8176)
- D. Wang (ORCID: https://orcid.org/0000-0003-3955-8143)
- Claire M. Midgley
- J. D. SINGLETON (ORCID: https://orcid.org/0009-0006-9714-268X)
Institutions
- University of Iowa (US)
- Centers for Disease Control and Prevention (US)
Publication Details
- Journal
- Open Forum Infectious Diseases
- Published
- 2024-11-08
- DOI
- https://doi.org/10.1093/ofid/ofae666
- Citations
- 3
- Primary Topic
- Influenza Virus Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.16
Funders
- Centers for Disease Control and Prevention